Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Lancet ; 366(9492): 1175-81, 2005 Oct 01.
Article in English | MEDLINE | ID: mdl-16198766

ABSTRACT

BACKGROUND: Adamantanes have been used to treat influenza A virus infections for many years. Studies have shown a low incidence of resistance to these drugs among circulating influenza viruses; however, their use is rising worldwide and drug resistance has been reported among influenza A (H5N1) viruses isolated from poultry and human beings in Asia. We sought to assess adamantane resistance among influenza A viruses isolated during the past decade from countries participating in WHO's global influenza surveillance network. METHODS: We analysed data for influenza field isolates that were obtained worldwide and submitted to the WHO Collaborating Center for Influenza at the US Centers for Disease Control and Prevention between Oct 1, 1994, and Mar 31, 2005. We used pyrosequencing, confirmatory sequence analysis, and phenotypic testing to detect drug resistance among circulating influenza A H3N2 (n=6524), H1N1 (n=589), and H1N2 (n=83) viruses. FINDINGS: More than 7000 influenza A field isolates were screened for specific aminoacid substitutions in the M2 gene known to confer drug resistance. During the decade of surveillance a significant increase in drug resistance was noted, from 0.4% in 1994-1995 to 12.3% in 2003-2004. This increase in the proportion of resistant viruses was weighted heavily by those obtained from Asia with 61% of resistant viruses isolated since 2003 being from people in Asia. INTERPRETATION: Our data raise concerns about the appropriate use of adamantanes and draw attention to the importance of tracking the emergence and spread of drug-resistant influenza A viruses.


Subject(s)
Adamantane/pharmacology , Antiviral Agents/pharmacology , Drug Resistance, Viral , Influenza A Virus, H3N2 Subtype , Influenza A virus/drug effects , Amino Acid Substitution , Humans , Influenza A virus/genetics , Virus Cultivation
2.
J Am Geriatr Soc ; 52(12): 2069-73, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15571544

ABSTRACT

OBJECTIVES: To prospectively detect amantadine-resistant influenza when amantadine was used for influenza A outbreak control. DESIGN: Prospective clinical surveillance and viral culture of all new respiratory illnesses during the course of amantadine prophylaxis. SETTING: A 721-bed, 14-ward nursing home for veterans and spouses during an influenza A outbreak (1993-94). PARTICIPANTS: Residents of a veterans hospital and their spouses. MEASUREMENTS: Nasopharyngeal and throat viral culture. All residents with positive cultures who developed new respiratory symptoms while receiving or residing on a unit receiving amantadine prophylaxis had antiviral-resistance testing and polymerase chain reaction restriction analyses performed. RESULTS: Amantadine prophylaxis was administered sequentially on nine of 14 wards to all well residents for 14 to 31 days/ward to control influenza outbreaks between December 9, 1993, and January 28, 1994. Amantadine treatment was simultaneously provided to 29 ill residents. Between December 3, 1993, and January 22, 1994, 68 culture-positive cases of influenza A were detected. Twenty subjects were receiving or residing on units receiving amantadine prophylaxis. Amantadine sensitivity testing could be performed on 16 residents; 12 residents had amantadine resistant strains. Four of the 12 had not received any antiviral treatment. Illness onset ranged from 1 to 22 days after amantadine prophylaxis was begun on the individual's unit. Two ribonucleic acid (RNA) mutations in the gene coding the M2 protein transmembrane region were observed that were clustered in time and space. Isolates from two roommates, one receiving amantadine for 18 days and one on no antiviral, had identical RNA sequences. CONCLUSION: Antiviral resistance may be responsible for failure of prophylaxis in nursing home outbreaks. Strategies that use different classes of antivirals for prophylaxis and treatment may limit emergence and transmission of resistant virus.


Subject(s)
Amantadine/pharmacology , Antiviral Agents/pharmacology , Cross Infection/prevention & control , Disease Outbreaks/prevention & control , Drug Resistance, Viral , Influenza A virus , Influenza, Human/prevention & control , Nursing Homes , Amantadine/therapeutic use , Antiviral Agents/therapeutic use , Cross Infection/epidemiology , Cross Infection/transmission , Humans , Influenza A virus/drug effects , Influenza, Human/epidemiology , Influenza, Human/transmission , Microbial Sensitivity Tests , Prospective Studies , Veterans , Wisconsin/epidemiology
3.
J Travel Med ; 10(6): 353-5, 2003.
Article in English | MEDLINE | ID: mdl-14642204

ABSTRACT

A 70-year-old male scientist, who had returned 5 weeks earlier from Ethiopia, was admitted to the hospital with symptoms consistent with malaria. On physical examination, he had orthostatic hypotension. He was dehydrated and showed a mild clinical delirium. Abdominal examination revealed a possible spleen tip, and he had petechial lesions bilaterally below his knees. Laboratory data revealed his white blood cell count to be 4,500/mL, with 67% polymorphonuclear cells and 15% band forms. The hemoglobin level was 13.9 g/dL, and the platelet count was low, at 32,000/mL.


Subject(s)
Antimalarials/therapeutic use , Malaria, Vivax/drug therapy , Malaria, Vivax/prevention & control , Naphthoquinones/therapeutic use , Proguanil/therapeutic use , Travel , Aged , Animals , Atovaquone , Cytochromes b/genetics , Drug Administration Schedule , Drug Combinations , Ethiopia , Humans , Malaria, Vivax/blood , Malaria, Vivax/diagnosis , Male , Plasmodium vivax/genetics , Polymorphism, Genetic , Sequence Analysis, DNA/methods , Treatment Failure , United States
4.
J Acquir Immune Defic Syndr ; 53(1): 14-9, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19801943

ABSTRACT

BACKGROUND: In 2006, a pediatric diarrhea outbreak occurred in Botswana, coinciding with heavy rains. Surveillance recorded a 3 times increase in cases and a 25 fold increase in deaths between January and March. Botswana has high HIV prevalence among pregnant women (33.4% in 2005), and an estimated 35% of all infants under the age of 6 months are not breastfed. METHODS: We followed all children <5 years old with diarrhea in the country's second largest referral hospital at the peak of the outbreak by chart review, interviewed mothers, and conducted laboratory testing for HIV and enteric pathogens. RESULTS: Of 153 hospitalized children with diarrhea, 97% were <2 years old; 88% of these were not breastfeeding. HIV was diagnosed in 18% of children and 64% of mothers. Cryptosporidium and enteropathogenic Escherichia coli were common; many children had multiple pathogens. Severe acute malnutrition (kwashiorkor or marasmus) developed in 38 (25%) patients, and 33 (22%) died. Kwashiorkor increased risk for death (relative risk 2.0; P = 0.05); only one breastfeeding child died. Many children who died had been undersupplied with formula. CONCLUSIONS: Most of the severe morbidity and mortality in this outbreak occurred in children who were HIV negative and not breastfed. Feeding and nutritional factors were the most important determinants of severe illness and death. Breastfeeding is critical to infant survival in the developing world, and support for breastfeeding among HIV-negative women, and HIV-positive women who cannot formula feed safely, may prevent further high-mortality outbreaks.


Subject(s)
Breast Feeding/epidemiology , Child Nutrition Disorders/epidemiology , Diarrhea/mortality , Disease Outbreaks , HIV Infections/epidemiology , HIV-1 , Anti-Bacterial Agents/adverse effects , Anti-Bacterial Agents/therapeutic use , Botswana/epidemiology , Breast Feeding/statistics & numerical data , Child Nutrition Disorders/microbiology , Child Nutrition Disorders/virology , Child, Preschool , Developing Countries , Diarrhea/drug therapy , Diarrhea/microbiology , Enterobacteriaceae/isolation & purification , Female , Follow-Up Studies , HIV Infections/microbiology , HIV Infections/transmission , Hospitalization/statistics & numerical data , Humans , Infant , Infant Formula/statistics & numerical data , Infant Mortality , Infectious Disease Transmission, Vertical/prevention & control , Infectious Disease Transmission, Vertical/statistics & numerical data , Mothers/statistics & numerical data , Risk Factors
SELECTION OF CITATIONS
SEARCH DETAIL